Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
about
Biomarkers of head and neck cancer, tools or a gordian knot?Tumor and stromal-based contributions to head and neck squamous cell carcinoma invasionNucleic acid targeting: towards personalized therapy for head and neck cancer.Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerAt the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of boneCurrent role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinomaToxin-based targeted therapy for malignant brain tumorsThe epidermal growth factor receptor variant III (EGFRvIII): where wild things are alteredToward the use of precision medicine for the treatment of head and neck squamous cell carcinomaEpidermal growth factor receptor in non-small cell lung cancerComprehensive genomic characterization of head and neck squamous cell carcinomasGenome stability pathways in head and neck cancersEGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cellsA pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastomaSpecific and sensitive hydrolysis probe-based real-time PCR detection of epidermal growth factor receptor variant III in oral squamous cell carcinomaThe mutational landscape of head and neck squamous cell carcinomaActivation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.Bioprocess development for the production of mouse-human chimeric anti-epidermal growth factor receptor vIII antibody C12 by suspension culture of recombinant Chinese hamster ovary cells.Where now for anti-EGF receptor therapies in colorectal cancer?Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment responseThe impact of sphingosine kinase-1 in head and neck cancer.Integration of biomarkers including molecular targeted therapies in head and neck cancer.Clinical update on cancer: molecular oncology of head and neck cancerPrognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.The quest to overcome resistance to EGFR-targeted therapies in cancer.Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.Genomics of squamous cell lung cancerEpidermal growth factor receptor variant III in head and neck squamous cell carcinoma is not relevant for targeted therapy and irradiation.Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapyA randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neckUnderstanding resistance to EGFR inhibitors-impact on future treatment strategiesAntibody-based immunotherapy for malignant glioma.Sphingosine kinase 1 mediates head & neck squamous cell carcinoma invasion through sphingosine 1-phosphate receptor 1.Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neckStrategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research SubcommitteeCurcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.Epidermal growth factor receptor expression in different subtypes of oral lichenoid diseaseCombination of phosphorylated and truncated EGFR correlates with higher tumor and nodal stage in head and neck cancerAn epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiformeImmunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
P2860
Q26784289-99BC7DC1-2AA0-4E8A-8694-D0E9085B1000Q26825164-6F3C2767-4E3C-4B49-B6C2-961628F87327Q26850237-97ADAA45-618C-4990-83C6-B4631E21253DQ26852215-36C866AB-4BB1-473A-860C-CB57DAE9336CQ26866067-D33E6B56-37FE-4D4F-8E96-959CC2FD08C2Q26991953-E22C8B87-0E58-42FB-99AB-9E9E89388BEDQ27006226-894169F3-3C1D-4971-8D46-7D833B10E69DQ27015045-4F3B2FA9-EEAC-4767-9B25-24C16BC4A45FQ28074691-AFA325A5-DDCB-4AFD-B9D0-2CA11AE66E48Q28088636-88E549B3-0477-4DBB-BF04-C98EAA506ECFQ28256121-3FB1C50F-CA44-412C-BBE2-280DB2A7EFC5Q28391355-564C98A9-2B1E-48AE-95DD-11694505B9B3Q28481290-80BF20A4-A81D-4621-9135-E79D28A33F91Q28731711-6B13D3CD-F008-419E-8B28-AAE55107E09FQ28732052-4D286A0C-2C21-4BCE-B9C5-5218D5CFC32DQ29614654-4CA4767B-C8E1-4D11-B563-30612E88D617Q30424348-42A9700C-ED61-48E7-A21D-63F951B23A30Q30467990-851922B6-C6BA-42F9-8CD2-B76353778953Q31038305-685D490F-D297-413D-AF45-B0122D79A39DQ31162700-D1F065C4-0580-4C08-9F44-ECB5FFFB40E3Q33649748-9CA625AA-C9BC-4A3D-B4C4-56F1E3ADEFC9Q33674090-35437D77-A714-45D8-BDAE-0CF4AF8B5360Q33695197-94D37C0A-20D8-4FD2-8697-24E10999A906Q33725229-3F526A4A-4139-4339-86B7-5AC74CEE8076Q33725976-2628D774-624A-410E-8321-EBFAA2B26849Q33767100-31CE2FAD-BCCB-4A81-90D7-13C7DD2087EBQ33777454-8F3BE25B-9436-4C79-8458-F7F6787CC328Q33779199-616BD3E4-98A1-4756-8E94-AB25392286D1Q33828409-B6C2561F-E35E-417C-BF14-ABF0AD38D09EQ34083131-253CC6C0-DF3B-4ADB-AB5B-AD7BC8FCC5F1Q34088424-EDF689B1-5863-4486-9BF8-B33C884BF9BAQ34120472-FF84E49E-4826-4EFD-ADCA-FD7D0E3278F6Q34135975-3E8CFF35-3FE2-4825-A1DF-16A14C5FE5EDQ34159125-E822AC01-F924-4D6A-B4E5-2FCBEB22C8C3Q34160540-8281359C-AC5E-4513-ABF8-1F9AE7FCDDACQ34163076-9152DF30-DC0D-4913-8D68-2FC447338C7EQ34317770-DA5A2491-F66D-4D2D-A7CB-3BDA824B222FQ34318204-95962002-4765-43AD-B733-60AF26017C3CQ34346944-72EB6DC9-0665-4A2F-8073-15695F26A61CQ34488771-11C1F9E2-F446-47B8-B60F-494F26ED4F54
P2860
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Mutant epidermal growth factor ...... resistance to EGFR targeting.
@en
type
label
Mutant epidermal growth factor ...... resistance to EGFR targeting.
@en
prefLabel
Mutant epidermal growth factor ...... resistance to EGFR targeting.
@en
P2093
P50
P1476
Mutant epidermal growth factor ...... resistance to EGFR targeting.
@en
P2093
Carol J Wikstrand
Francesca M Coppelli
Jennifer L Hunt
John C Sok
Maria L Freilino
Michael W Graner
Miriam N Lango
Sichuan Xi
William E Gooding
P304
P356
10.1158/1078-0432.CCR-06-0913
P407
P577
2006-09-01T00:00:00Z